S. Athalye

发表

A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

N. Czeloth, B. Lang, Willem Hettema, 2017, Expert opinion on investigational drugs.

Steady-State Pharmacokinetics of Rivastigmine in Patients with Mild to Moderate Alzheimer’s Disease Not Affected by Co-Administration of Memantine

G. Sedek, F. Picard, G. Lefèvre, 2008, Clinical drug investigation.

P4-410 Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease are not affected by co-administration of memantine

G. Sedek, G. Lefèvre, F. Pommier, 2006, Alzheimer's & Dementia.

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study

T. Blevins, Y. Raiter, A. Barve, 2018, Diabetes, obesity & metabolism.

Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus

H. Lebovitz, A. Cherrington, A. Fleming, 2019, Clinical pharmacology in drug development.

Efficacy and Safety of Tregopil, a Novel, Ultra-Rapid Acting Oral Prandial Insulin Analog, as Part of a Basal-Bolus Regimen in Type 2 Diabetes: A Randomized, Active Controlled Phase 3 Study

H. Lebovitz, A. Cherrington, J. Panda, 2022, medRxiv.

Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open‐Label, Placebo‐Controlled, Crossover Study

H. Lebovitz, A. Cherrington, A. Fleming, 2019, Clinical and translational science.

Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study

H. Lebovitz, A. Cherrington, A. Fleming, 2022, Expert opinion on pharmacotherapy.

Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications

S. Joshi, S. Athalye, S. Loganathan, 2020, Expert opinion on biological therapy.

REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV Itolizumab Trial: RESURRECT

S. Athalye, B. Thakur, Chirag C Rathod, 2021, medRxiv.

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

R. Guleria, S. Joshi, A. Trikha, 2020, medRxiv.

Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective.

S. Joshi, V. Suvarna, S. Athalye, 2022, Expert opinion on biological therapy.

Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

T. Blevins, Y. Raiter, A. Barve, 2019, Diabetes, obesity & metabolism.

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study

S. Athalye, S. Loganathan, A. Marwah, 2021, Diabetes, obesity & metabolism.

Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta‐analysis

V. Suvarna, Shashank R Joshi, S. Athalye, 2023, Diabetes, obesity & metabolism.

Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects

Benjamin Lang, Rod Ellis-Pegler, N. Czeloth, 2016, Expert opinion on investigational drugs.

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE‐2 (Recombinant Human INsulin Equivalence‐2) study

G. Andersen, S. Athalye, S. Loganathan, 2023, Diabetes, obesity & metabolism.

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study

O. Klein, S. Athalye, S. Loganathan, 2022, Diabetes, obesity & metabolism.

Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus

S. Joshi, V. Sambandamurthy, S. Athalye, 2023, Drugs.

REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT

S. Athalye, Chirag C Rathod, S. Loganathan, 2023, Expert Opinion on Biological Therapy.